Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model

To date, two published randomized trials have indicated a clinical benefit of early treatment with fluvoxamine versus placebo for adults with symptomatic COVID-19. Using the results of the largest of these trials, the TOGETHER trial, we conducted a cost–consequence analysis to assess the health syst...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Fergal P., Reis, Gilmar, Wilson, Lindsay A., Thorlund, Kristian, Forrest, Jamie I., Guo, Christina M., Boulware, David R., Mills, Edward J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833089/
https://www.ncbi.nlm.nih.gov/pubmed/36379209
http://dx.doi.org/10.4269/ajtmh.22-0106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833089/
https://www.ncbi.nlm.nih.gov/pubmed/36379209
http://dx.doi.org/10.4269/ajtmh.22-0106

Ejemplares similares